NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
Clinical Trials
17 trialsNCT02682641 2024-02-26
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Unknown
NCT02471391 2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04522284 2023-03-29
PRECISE CURATE.AI Pilot Clinical Trial
National University Hospital, Singapore
Phase 1/2 Unknown
NCT03280160 2022-09-16
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
PETHEMA Foundation
Phase 2 Unknown
NCT04514393 2022-04-07
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT02689869 2021-05-07
Alternative
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT02884453 2019-09-18
iMYC
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT04094051 2019-09-18
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT03642236 2018-08-22
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02991638 2018-04-12
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
The University of Hong Kong
Phase 3 Unknown
NCT02912754 2017-03-13
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Sunnybrook Health Sciences Centre
Phase 1/2 Unknown
NCT02955628 2017-02-14
RICE-ibrutinib in Relapsed DLBCL
Singapore General Hospital
Phase 2 Unknown
NCT02757040 2016-04-29
Combination of Ibrutinib and As2O3 in the Treatment of CLL
Peking University People's Hospital
Phase 3 Unknown